Background Multiple sclerosis (MS) is the most common neurological cause of disability in
young adults. Off‐label rituximab for MS is used in most countries surveyed by the …

Background Multiple sclerosis (MS) is an immune‐mediated, chronic, inflammatory
demyelinating disease of the central nervous system, impacting around 2.8 million people …

Background Multiple sclerosis is an inflammatory demyelination process in the central
nervous system (CNS) causing neurological disability and poor quality of life. Currently, Thai …

Objectives Guidelines and essential medicine lists (EMLs) bear similarities and differences
in the process that lead to decisions. Access to essential medicines is central to achieve …

Therefore, in the current situation with this momentous result, implementation of the WHO
EML through the IGAP, or similar, frameworks will require coordinated leadership at national …

Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For
a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the …

Background Until recently, few therapeutic options, other than symptomatic treatment, were
available for patients with primary progressive multiple sclerosis (PPMS). Ocrelizumab is the …

Background A total of 2.8 million people are living with multiple sclerosis and due to
disparities in access to medicines, the ability to treat this condition varies widely. Off-label …

Objectives Guidelines and essential medicine lists (EMLs) bear similarities and differences
in the process that lead to decisions. Access to essential medicines is central to achieve …

Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory-
demyelinating disorder of the central nervous system (CNS). It usually begins in young …